Establishment and Characteristics of a Novel Mantle Cell Lymphoma-derived Cell Line and a Bendamustine-resistant Subline.

about

Establishment and Characteristics of a Novel Mantle Cell Lymphoma-derived Cell Line and a Bendamustine-resistant Subline.

Item

http://www.wikidata.org/entity/Q52563039

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Establishment and Characterist ...... endamustine-resistant Subline.

@en

Establishment and Characterist ...... endamustine-resistant Subline.

@nl

type

Item

label

Establishment and Characterist ...... endamustine-resistant Subline.

@en

Establishment and Characterist ...... endamustine-resistant Subline.

@nl

prefLabel

Establishment and Characterist ...... endamustine-resistant Subline.

@en

Establishment and Characterist ...... endamustine-resistant Subline.

@nl

P1476

Establishment and Characterist ...... endamustine-resistant Subline.

@en

P2093

Hisao Nagoshi

http://www.w3.org/2001/XMLSchema#string

Junya Kuroda

http://www.w3.org/2001/XMLSchema#string

Masafumi Taniwaki

http://www.w3.org/2001/XMLSchema#string

Saori Maegawa

http://www.w3.org/2001/XMLSchema#string

Shigeo Horiike

http://www.w3.org/2001/XMLSchema#string

Shinsuke Mizutani

http://www.w3.org/2001/XMLSchema#string

Taku Tsukamoto

http://www.w3.org/2001/XMLSchema#string

Tomoko Takimoto-Shimomura

http://www.w3.org/2001/XMLSchema#string

Tsutomu Kobayashi

http://www.w3.org/2001/XMLSchema#string

Yayoi Matsumura-Kimoto

http://www.w3.org/2001/XMLSchema#string

P2860

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.

Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.

Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.

Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.

TP53 mutations in human cancers: origins, consequences, and clinical use

Pharmacological strategies for overcoming multidrug resistance.

P-Glycoprotein/MDR1 regulates pokemon gene transcription through p53 expression in human breast cancer cells

Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents.

P304

213-223

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.21873/CGP.20080

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29695404

http://www.w3.org/2001/XMLSchema#string

P921

cell line

P932

5971014

http://www.w3.org/2001/XMLSchema#string